Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZ0T24)

Drug Name
Abagovomab Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2/3 [1]
Cross-matching ID
TTD Drug ID
DMZ0T24

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ovarian carcinoma antigen CA125 (MUC16) TTC1PS3 MUC16_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 1.138 1.585 1.322 1.322
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Ovarian tissue
The Studied Disease Ovarian cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 4.86E-04 5.02 2.6
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8265).
2 Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.